Biomedical R&D company
The application for the listing of generic copy of Apster tablets of CSPC is accepted by CDE and is currently under review and approval. Apster tablets are heavyweight products of Xinji Pharmaceutical, which were later acquired by Amgen at a high price. At present, there is no such product imported or generic drugs listed on the domestic market. CSPC Europe is also the only pharmaceutical company currently applying for listing
Shenzhou Cell had previously reached a commercial agreement with CSPC on the product under study SCT400, but based on the changes in the pharmaceutical policy and market environment in the past year, CSPC proposed to Shenzhou Cell to modify the "Commercialization Agreement". Follow-up did not reach agreement on the amendment of the agreement. . CSPC just ended its cooperation with another innovative pharmaceutical company, Junshi Biology. On December 30, CSPC issued an announcement that in order to avoid potential conflicts that may arise from clinical research and future commercialization of another anti-PD-1 monoclonal antibody drug under investigation, the company and Junshi Zao The previously signed cooperation on R & D and commercialization of breast cancer drugs was concluded on December 30, 2019.
Forbes China launched the "Outstanding Leaders of Chinese Enterprises' Multinational Operations" list for the first time. Of the 50 outstanding Chinese business leaders, 4 of them are from the pharmaceutical industry. They are Cai Dongchen, Xinhecheng's Hu Baiyan and WuXi of CSPC. Li Ge of Kant and Wu Yifang of Fosun Pharma.
Based on the company ’s lower-than-expected annual report performance, the net profit attributable to mothers in 2020-2021 was lowered from 47.33 and 64.77 to 4.331 billion and 5.072 billion yuan, and the net profit attributable to mothers in 2022 was increased by 6.012 billion yuan, up 16.6% and 17.1% year-on-year. 18.5%
It is estimated that the company's net profit attributable to the mother in 2020-2022 will be 4.33 billion yuan, 5.19 billion yuan and 6.134 billion yuan respectively, with corresponding growth rates of 16.6%, 19.8% and 18.3%, and EPS of 0.69 yuan / share and 0.83 yuan / share. Shares and 0.98 yuan / share